GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Gross Profit

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Gross Profit : $0.00 Mil (TTM As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Gross Profit?

CERo Therapeutics Holdings's gross profit for the six months ended in Dec. 2022 was $0.00 Mil. CERo Therapeutics Holdings's gross profit for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. CERo Therapeutics Holdings's gross profit for the six months ended in Dec. 2022 was $0.00 Mil. CERo Therapeutics Holdings's Revenue for the six months ended in Dec. 2022 was $0.00 Mil. Therefore, CERo Therapeutics Holdings's Gross Margin % for the quarter that ended in Dec. 2022 was N/A%.

CERo Therapeutics Holdings had a gross margin of N/A% for the quarter that ended in Dec. 2022 => No sustainable competitive advantage


CERo Therapeutics Holdings Gross Profit Historical Data

The historical data trend for CERo Therapeutics Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Gross Profit Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Gross Profit
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Gross Profit - -

Competitive Comparison of CERo Therapeutics Holdings's Gross Profit

For the Biotechnology subindustry, CERo Therapeutics Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Gross Profit falls into.



CERo Therapeutics Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

CERo Therapeutics Holdings's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

CERo Therapeutics Holdings's Gross Profit for the quarter that ended in Dec. 2022 is calculated as

Gross Profit (Q: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Gross Profit for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

CERo Therapeutics Holdings's Gross Margin % for the quarter that ended in Dec. 2022 is calculated as

Gross Margin % (Q: Dec. 2022 )=Gross Profit (Q: Dec. 2022 ) / Revenue (Q: Dec. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


CERo Therapeutics Holdings  (NAS:CERO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

CERo Therapeutics Holdings had a gross margin of N/A% for the quarter that ended in Dec. 2022 => No sustainable competitive advantage


CERo Therapeutics Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines